Enhanced internalization of ErbB2 in SK-BR-3 cells with multivalent forms of an artificial ligand

Arun Vaidyanath1, Toshihiro Hashizume, Tadahiro Nagaoka

  • 1Laboratory of Nano-Biotechnology, Department of Medical Bioengineering Science, Graduate School of Natural Science and Biotechnology, Okayama University, Kita-ku, Okayama, Japan.

Insights

Multivalent forms of the artificial ErbB2 ligand EC-1, particularly when displayed on bionanocapsules, effectively induce ErbB2 internalization in cancer cells via the GEEC pathway.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • ErbB2 (Epidermal Growth Factor Receptor family member 2) is a key target in cancer therapy, often overexpressed in breast and ovarian cancers.
  • Natural ligands for ErbB2 are unknown, but the artificial ligand EC-1 peptide binds ErbB2.

Purpose of the Study:

  • To enhance ErbB2 binding and induce internalization using multivalent forms of the EC-1 peptide.
  • To investigate the internalization pathway of ErbB2 induced by multivalent EC-1.

Main Methods:

  • Design and synthesis of divalent and multivalent EC-1 peptide conjugates (EC-Fc, bionanocapsule-displayed EC-1).
  • Assessment of ErbB2 binding affinity and induction of ErbB2 internalization in SK-BR-3 cells.
  • Investigation of internalization pathways by inhibiting clathrin and depleting cholesterol.

Main Results:

  • Multivalent EC-1 forms exhibited higher affinity for ErbB2 than monomeric EC-1.
  • Multivalent EC-1 on bionanocapsules induced significant ErbB2 endosomal accumulation in SK-BR-3 cells.
  • ErbB2 internalization was cholesterol-dependent and clathrin-independent, suggesting the GEEC pathway.

Conclusions:

  • Multivalent display of EC-1 significantly improves ErbB2 interaction and induces internalization.
  • The GEEC pathway is the primary mechanism for ErbB2 internalization induced by multivalent EC-1 in SK-BR-3 cells.
  • This strategy offers a novel approach for targeting ErbB2 in cancer treatment.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: